Tvardi Therapeutics Inc
TVRD
Company Profile
Business description
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USAT: +1 713 489-8654
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,504.80 | 37.80 | 0.45% |
| CAC 40 | 7,850.10 | 106.35 | 1.37% |
| DAX 40 | 23,566.54 | 67.22 | 0.29% |
| Dow JONES (US) | 42,410.10 | 1,160.72 | 2.81% |
| FTSE 100 | 8,604.98 | 50.18 | 0.59% |
| HKSE | 23,230.86 | 318.60 | -1.35% |
| NASDAQ | 18,708.34 | 779.43 | 4.35% |
| Nikkei 225 | 38,282.28 | 638.02 | 1.69% |
| NZX 50 Index | 12,786.74 | 109.99 | 0.87% |
| S&P 500 | 5,844.19 | 184.28 | 3.26% |
| S&P/ASX 200 | 8,263.20 | 29.70 | 0.36% |
| SSE Composite Index | 3,376.08 | 6.84 | 0.20% |